With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.
Events
Mar 30, 2021 at 4:30 PM EDT
Mar 20 - Mar 23, 2021
Feb 24, 2021 from 4:20 PM to 4:50 PM EST
Press Releases
April 12, 2021
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
Crinetics has closed its previously announced follow-on offering, proceeds from which will fund, in part, the continued development of paltusotine for acromegaly as well as other R&D programs.
April 7, 2021
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share.
Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.
Investor Resources
Data Provided by Refinitiv. Minimum 15 minutes delayed.